WERI-Rb-1 Xenograft Model Service for Retinoblastoma

The WERI-Rb-1 xenograft model offers a well-characterized, clinically relevant platform for evaluating novel therapeutic strategies against retinoblastoma, the most common intraocular malignancy in children. Alfa Cytology provides a comprehensive WERI-Rb-1 xenograft model service tailored for preclinical retinoblastoma research, combining robust tumor engraftment with integrated pharmacodynamic and pharmacokinetic evaluation to accelerate your drug development pipeline.

Overview of WERI-Rb-1 Xenograft Model for Retinoblastoma

Retinoblastoma is the most common malignant intraocular tumor of childhood, arising from the developing retina with an incidence of approximately 1 in 15,000 to 20,000 live births worldwide. The WERI-Rb-1 cell line, established in 1974 from a primary tumor of the right eye of a one-year-old Caucasian female without familial history, represents one of the two most widely characterized human retinoblastoma models available for research. When propagated as a xenograft in immunodeficient mice, WERI-Rb-1 cells form localized intraocular tumors that recapitulate key histopathological features of human retinoblastoma, including the formation of Flexner-Wintersteiner rosettes, while exhibiting a less aggressive, non-metastatic phenotype compared to the Y79 model. This makes the WERI-Rb-1 xenograft particularly valuable for studying localized disease progression and evaluating localized therapeutic interventions.

The WERI-Rb-1 xenograft model has been extensively utilized in preclinical studies to investigate chemotherapy resistance mechanisms, evaluate novel drug delivery systems including nanoparticle-based ocular therapeutics, and assess the efficacy of targeted agents. The cell line retains expression of neuronal markers and photoreceptor-specific genes, offering a biologically faithful platform for mechanism-of-action studies. Its near-diploid karyotype and well-documented genetic background, including RB1 gene alterations, provide a solid foundation for translational research aimed at understanding retinoblastoma pathophysiology and developing next-generation treatments.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting retinoblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving retinoblastoma progression and chemotherapy resistance, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Determination of the IC50 of rapamycin on the biglycan (BGN) group and the normal control (NC) group of human WERI-Rb-1 retinoblastoma (RB) cells determined using the MTT assay. (Fang, Dong, et al., 2019)

Cell Line Information: WERI-Rb-1

The WERI-Rb-1 cell line is one of the most extensively characterized human retinoblastoma models, with a well-documented origin, genetic profile, and phenotypic properties. Its ability to form Flexner-Wintersteiner rosettes and retain photoreceptor-specific gene expression makes it unique among available retinoblastoma cell lines and essential for faithful disease modeling.

Our Services

Alfa Cytology leverages the WERI-Rb-1 xenograft platform to deliver end-to-end preclinical retinoblastoma research services, from tumor cell inoculation and engraftment monitoring through to comprehensive endpoint analysis including tumor burden quantification, histopathological evaluation, and biomarker assessment. Our experienced team ensures reproducible model performance with rigorous quality control, enabling you to generate reliable pharmacological data for your retinoblastoma therapeutic programs.

Workflow of WERI-Rb-1 Xenograft Model Construction

The construction of a WERI-Rb-1 xenograft model follows a standardized, multi-step protocol designed to ensure consistent tumor engraftment, reliable growth kinetics, and clinically relevant tumor progression for robust preclinical evaluation. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: WERI-Rb-1 cells are expanded in suspension culture under optimal conditions (RPMI-1640 + 10% FBS, 37 degrees C, 5% CO2) and harvested during the logarithmic growth phase. Cell viability is confirmed by trypan blue exclusion (>=95% viability required), and mycoplasma contamination is ruled out by PCR testing prior to inoculation.
2. Recipient Animal Selection and Preparation: Immunodeficient mice (commonly NOD-SCID, NSG, or BALB/c nude mice, 6--8 weeks old) are selected based on study objectives. Animals are acclimatized for one week and randomized into treatment groups, with baseline ophthalmic examinations performed to exclude pre-existing ocular abnormalities.
3. Tumor Cell Inoculation: WERI-Rb-1 cells are resuspended in a serum-free medium or Matrigel/PBS mixture at a predetermined concentration (typically 1x10^6 to 5x10^6 cells per injection). For orthotopic models, cells are delivered via intravitreal injection; for subcutaneous models, cells are injected into the flank. Injection volume and rate are carefully controlled to minimize reflux and tissue damage.
4. Tumor Engraftment Monitoring: Tumor growth is monitored by palpation (subcutaneous) or non-invasive imaging modalities including funduscopy, optical coherence tomography (OCT), and bioluminescence imaging (if luciferase-labeled cells are used). Tumor dimensions are measured with calipers twice weekly, and tumor volume is calculated using the formula: (length x width^2) / 2.
5. Treatment Administration: Upon reaching a predefined tumor volume (typically 100--200 mm^3 for subcutaneous, or established intraocular tumor for orthotopic), animals are randomized into vehicle control and treatment groups. Test compounds are administered via the route specified by the study protocol (intravenous, intravitreal, periocular, or oral gavage) on a defined dosing schedule.
6. Endpoint Analysis and Sample Collection: At study termination, animals are euthanized humanely. Tumors are excised, weighed, and photographed. Tissue samples are fixed in formalin for histopathological analysis (H&E, IHC for Ki-67, CD133, RB1, etc.), snap-frozen for protein/RNA analysis, or processed for flow cytometry. Ocular tissues are examined for tumor invasion patterns and retinal architecture preservation.

Figure 2: Schematic workflow illustrating the derivation and construction of the WERI-Rb-1 Xenograft Model at Alfa Cytology.

Case Study-WERI-Rb-1 Xenograft Model Development

Alfa Cytology has successfully established and validated the WERI-Rb-1 xenograft model across multiple study designs, demonstrating consistent tumor take rates, predictable growth kinetics, and dose-dependent responses to standard-of-care chemotherapeutic agents. Our internal dataset encompasses tumor growth curves, survival analyses, histopathological correlations, and pharmacodynamic biomarker profiles. Detailed case study data, including quantitative efficacy metrics and representative imaging, are available upon request---please contact our scientific team to discuss your specific research requirements and receive a customized data package.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering high-quality, reproducible preclinical tumor models that accelerate your therapeutic development. Our WERI-Rb-1 xenograft service is distinguished by the following advantages:

• Verified Cell Line Integrity: Validated model performance with documented tumor take rates and consistent growth kinetics across multiple independent studies.
• High Take Rates and Consistency: Comprehensive study design flexibility, including both subcutaneous and orthotopic (intravitreal) implantation routes tailored to your therapeutic modality.
• Comprehensive Analytical Support: Integrated pharmacodynamic and pharmacokinetic evaluation with histopathology, biomarker analysis, and ocular imaging capabilities.
• Tailored Study Designs: Experienced scientific team with deep expertise in pediatric ocular oncology models and retinoblastoma biology.
• Standardized Protocols: Rigorous quality control at every stage, from cell line authentication and pathogen screening to GLP-compliant data reporting.
• Dedicated Project Management: Customizable dosing schedules, combination therapy arms, and co-clinical biomarker strategies to support your development program.

Contact Us

Ready to advance your retinoblastoma therapeutic program with a validated WERI-Rb-1 xenograft model? Contact us today to discuss your project requirements, receive a detailed study proposal, and learn how Alfa Cytology can support your preclinical research objectives. Please reach out to us today via our inquiry form or email to learn more about our WERI-Rb-1 Xenograft Model services.

For research use only. Not intended for any clinical use.